The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s angiotensin receptor blockers ARBs market report forecasts the angiotensin receptor blockers ARBs market size to grow to $9.40 Billion by 2027, with a CAGR (compound annual growth rate) of more than 3%.

Learn More On The Angiotensin Receptor Blockers ARBs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Angiotensin Receptor Blockers ARBs Market Size Forecast
The global angiotensin receptor blockers ARBs market is expected to grow from $8.02 billion in 2022 to $8.30 billion in 2023 at a compound annual growth rate (CAGR) of 3.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global angiotensin receptor blockers (ARBs) market size is expected to grow to $9.40 billion in 2027 at a CAGR of 3.2%.

North America held the largest angiotensin receptor blockers ARBs market share.

Key Angiotensin Receptor Blockers ARBs Market Driver ­– Increase In The Incidence Of Cardiovascular Diseases
According to a report published by the Centers for Disease Control and Prevention, a US-based international organisation responsible for public health, over 697,000 people died from heart disease in the United States in 2020, accounting for one out of every five deaths. As a result, the rising prevalence of cardiovascular diseases is propelling the angiotensin receptor blockers market forward.

Request for A Sample Of The Global Angiotensin Receptor Blockers ARBs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

Key Angiotensin Receptor Blockers ARBs Market Trend – Product Innovation
Major players in the angiotensin receptor blocker market are focusing on developing innovative solutions to strengthen their market position. For example, Novartis AG, a Swiss pharmaceutical company, will launch Entresto (sacubitril/valsartan) in February 2021. The US Food and Drug Administration has granted Entresto (sacubitril/valsartan) an expanded indication to reduce the risk of cardiovascular death and hospitalisation for heart failure in adult patients with chronic heart failure. Patients with a lower-than-normal left ventricular ejection fraction benefit the most (LVEF). Entresto is the first and only therapy approved in the United States for the treatment of patients with guideline-defined heart failure, which includes both those with reduced ejection fraction (HFrEF) and many with preserved ejection fraction (HFpEF).

Angiotensin Receptor Blockers ARBs Market Segment
1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Angiotensin Receptor Blockers ARBs Market Major Players and Strategies
Major players in the angiotensin receptor blockers ARBs market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GSK Plc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., Lupin Pharmaceuticals Inc., Astellas Pharma Inc., and Boehringer Ingelheim Ltd.

The Angiotensin Receptor Blockers ARBs Global Market Report 2023 covers regional data on angiotensin receptor blockers ARBs market size, angiotensin receptor blockers ARBs market trends and drivers, opportunities, strategies, and angiotensin receptor blockers ARBs market competitor analysis. The countries covered in the angiotensin receptor blockers ARBs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Angiotensin receptor blockers (ARBs) are drugs that dilate (widen) blood vessels and are used to treat diabetes-related conditions such as high blood pressure (hypertension), heart failure, and kidney disease. Angiotensin is a chemical that causes blood vessels to constrict in the body. This constriction can cause blood pressure to rise and the heart to work harder.

View More Reports Related To The Angiotensin Receptor Blockers ARBs Market –
AntiHypertensive Drugs Global Market Report 2023
Antiglaucoma Drugs Global Market Report 2023
Bipolar Disorder Therapeutics Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: